Home Hero
Home Hero

For your patients’ hypereosinophilic
syndrome (HES)

Help bring
back balance

by reducing HES flares

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

Choose NUCALA for proven protection from flares1

Randomized, 

placebo-controlled trial

72%

of patients had

ZERO flares vs

44% with placebo

Results are descriptive.

Primary endpoint results: Proportion of patients who experienced HES flare(s)* during the 32-week study or withdrew. NUCALA 28% vs placebo 56%, P=0.002.

*HES flare: Worsening of clinical signs/symptoms or increased eosinophils (on ≥2 occasions), resulting in an escalation/addition of oral corticosteroids (OCS) or cytotoxic or immunosuppressive therapy.

Identifying hypereosinophilic syndrome (HES) icon

Identifying HES

The definition, clinical manifestations, and more

Shield icon

Flare reduction

Proportion of patients with flares and time to first flare

Eosinophil reduction icon

Eosinophil reduction and mechanism of action (MOA)

See the results of NUCALA on eosinophil reduction